ストックスクリーナーアプリを入手
4.67
2.71%
-0.13
前日終値:
$4.80
開ける：
$4.87
24時間の取引高:
16,520
Relative Volume:
0.44
時価総額：
$5.82M
収益：
$12.99M
当期純損益:
$-27.83M
株価収益率:
-0.0229
EPS:
-203.7366
ネットキャッシュフロー:
$-26.98M
1週間 パフォーマンス:
-3.91%
1か月 パフォーマンス:
+0.86%
6か月 パフォーマンス:
-75.05%
1年 パフォーマンス:
-94.94%
1日の値動き範囲:
$4.6699
$4.87
1週間の範囲:
$4.50
$4.91
52週間の値動き範囲:
$3.80
$91.44
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Compare APVO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.67 | 5.82M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
Aptevo Therapeutics Inc (APVO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate
APVO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces HeadwindsPretax Income Report - newsline.com
Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan
Aptevo names Mary Janatpour as chief scientific officer - Investing.com UK
Aptevo Therapeutics Names Mary Janatpour Chief Scientific Officer as It Expands Beyond Core Immuno-Oncology Programs - citybiz
Aptevo names Mary Janatpour as chief scientific officer By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer - ACCESS Newswire
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Black Hills Pioneer
Seattle biotech lands investment, collaboration deal for cancer treatments - The Business Journals
Aptevo and Niowave Partner to Develop Radiopharmaceuticals; Niowave to Invest in Aptevo - geneonline.com
Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave - TipRanks
Aptevo Therapeutics (APVO) Forms Strategic Collaboration with Ni - GuruFocus
APVO Q1 2026 Earnings: EPS Miss Widens as Revenue Remains AbsentEarnings Preview - The Legal Advocate
Aptevo and Niowave launch radiopharmaceuticals collaboration - The Pharma Letter
Aptevo, Niowave form 50/50 partnership for cancer drugs By Investing.com - Investing.com Nigeria
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, I - PharmiWeb.com
Aptevo, Niowave form 50/50 partnership for cancer drugs - Investing.com
Niowave takes 7.9% Aptevo stake in cancer radiopharma tie-up - Stock Titan
APVO Q1 2026 Earnings: Stock Rises Despite Wider-Than-Expected Loss as Pipeline Progress Takes Center Stage - The Legal Advocate
APVO Q1 2026 Earnings: Stock Gains Sharply Despite Wider-Than-Expected LossShare Dilution Risk - The Legal Advocate
Aptevo (APVO) Q1 2026 Earnings: Soft Quarter Raises QuestionsEarnings Miss Alert - Newser
All you need to know about Aptevo Therapeutics (APVO) rating upgrade to buy - MSN
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy - Yahoo Finance
Aptevo (APVO) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Consistency Score - Newser
Key facts: Aptevo Q1 loss $0.01/sh; mipletamig shows 87% clinical benefit - TradingView
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports clinical trial results for AML drug candidate By Investing.com - Investing.com India
Aptevo (APVO) Positioned for Growth with Promising Pipeline and Leadership - GuruFocus
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo Therapeutics (NASDAQ: APVO) warns on going concern after $6.7M Q1 loss - Stock Titan
Strong AML data and $60M equity facility in Aptevo (NASDAQ: APVO) Q1 update - Stock Titan
Aptevo Therapeutics Updates on Q1 2026 Progress and Leadership T - GuruFocus
Aptevo reports clinical trial results for AML drug candidate - Investing.com UK
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - ACCESS Newswire
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):